Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
Sci Transl Med. 2022 Jun 8;14(648):eabj2658. doi: 10.1126/scitranslmed.abj2658. Epub 2022 Jun 8.
Sci Transl Med. 2022.
PMID: 35675433